"Astrazeneca going beyond - reshaping the blockbuster business model"

AstraZeneca (AZN) is a global, science-led biopharmaceutical company focused on on the discovery, development, and commercialisation drugs, primarily for the treatment of diseases in three main areas Oncology, Cardiovascular, Respiratory. From 2021 AstraZeneca added anew segment to its business ±Rar...

Full description

Bibliographic Details
Main Author: Revalska, Petya Sergeeva (author)
Format: masterThesis
Language:eng
Published: 2022
Subjects:
Valuation
Finance
Covid-19 pandemic
Astrazeneca
Alexion
Oncology
Rare diseases
Collaboration agreements
Drug Sales
Blockbuster Business Model
Acquisition
Pharmaceuticals
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
Online Access:http://hdl.handle.net/10362/144641
Country:Portugal
Oai:oai:run.unl.pt:10362/144641
Description
Summary:AstraZeneca (AZN) is a global, science-led biopharmaceutical company focused on on the discovery, development, and commercialisation drugs, primarily for the treatment of diseases in three main areas Oncology, Cardiovascular, Respiratory. From 2021 AstraZeneca added anew segment to its business ±Rare Diseases by acquiring Alexion Pharmaceutical, Inc. This paper aims to value AstraZeneca by using methods such as discounted cash flows and trading multiples. I intend to estimate the company enterprise value as of 30-12-2022 and provide an investment recommendation for 12-month period.

Similar Items